A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

Clinical and Vaccine Immunology

Volumn 17, Issue 11, 2010, Pages 1817-1819

  Fragapane, Elena ^a   Gasparini, Roberto ^b   Schioppa, Francesco ^c   Laghi Pasini, Franco ^d   Montomoli, Emanuele ^e   Banzhoff, Angelika ^f  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLUNOV; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHILL; CLADISTICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MYALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; YOUNG ADULT;

EID: 78449255270     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00461-09     Document Type: Article

References (12)

1. Atmar, R. L., W. A. Keitel, S. M. Patel, et al. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43:1135-1142.
2. Banzhoff, A., R. Gasparini, F. Laghi-Pasini, et al. 2009. Pre-pandemic influenza immunization: MF59-adjuvanted H5N1 vaccine induces immunogenic memory and heterotypic antibody response in non-elderly and elderly adults. PLoS One 4:e4384.
3. Banzhoff, A., M. Pellegrini, G. Del Giudice, E. Fragapane, N. Groth, and A. Podda, 2008. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir. Viruses 2:243-249.
4. Committee for Proprietary Medicinal Products. 1997. Note for guidance on harmonization of requirements for influenza vaccines CPMP/BWP/214/96. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
5. Jennings, L. C., A. S. Monto, P. K. Chan, T. D. Szucs, and K. G. Nicholson. 2008. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8:650-658.
6. Lin, J. T., C. G. Li, X. Wang, et al. 2009. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J. Infect. Dis. 199:184-187.
7. Monto, A. S. 2009. The risk of seasonal and pandemic influenza: prospects for control. Clin. Infect. Dis. 48(Suppl. 1):S20-S25.
8. Nicholson, K. G., A. E. Colegate, A. Podda, et al. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943.
9. Nolan, T., P. C. Richmond, M. V. Skeljo, et al. 2008. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26:4160-4167.
10. Stephenson, I., R. Bugarini, K. G. Nicholson, et al. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191:1210-1215.
11. Stephenson, I., K. G. Nicholson, A. Colegate, et al. 2003. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21:1687-1693. (Pubitemid 36287599)
12. World Health Organization. Accessed 17 March 2008. Responding to the avian influenza pandemic threat: recommended strategic actions. http://www.who.int/csr/resouces/publications/influenza/WHO-CDS-CSR-GIP-05-8-EN. pdf. World Health Organization, Geneva, Switzerland.